In this issue:
Pioglitazone + imatinib in CML
Non-del(5q) low-risk MDS after erythropoiesis-stimulating agent failure
BTK C481S-mediated resistance to ibrutinib in CML
Late relapse of classical Hodgkin lymphoma
Sequencing of ibrutinib, idelalisib and venetoclax in CLL
Idelalisib in R/R classical Hodgkin lymphoma
Targeting role of lymphocyte activation gene 3 in CLL
Genetic profiling of MYC and BCL2 in DLBCL
Nivolumab after alloSCT for relapsed Hodgkin lymphoma
Ibrutinib in R/R marginal zone lymphoma
Please login below to download this issue (PDF)